Unmet needs in HER2+ MBC
Lecture Summary - ASCO 2022 Preliminary Analysis of an Expanded Access Study of the Fixed-Dose Combination of Pertuzumab & Trastuzumab for Subcutaneous Injection for At-Home Administration in HER2+ BC During the COVID-19 Pandemic
By
ASCO 2022 Conference Coverage
FEATURING
Chau Dang
By
ASCO 2022 Conference Coverage
FEATURING
Chau Dang
Comments 0
Login to view comments.
Click here to Login